// App-Quantinova.ai

TPS5082 : ERA 223: A phase 3 trial of radium-223 dichloride (Ra-223) in combination with abiraterone acetate (abiraterone) and prednisone in the treatment of asymptomatic or mildly symptomatic chemotherapy-nave patients (pts) with bone predominant metastatic castration-resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Matthew Raymond Smith

Principal Investigators

  • Chris Parker

  • Fang Fang

  • Amily Zhang

  • Martin Kornacker

  • Celestia S. Higano

  • Bertrand F. TombAlKurt Miller

  • Fred Saad

Medical Centers

  • Charite-University Medicine Berlin, Berlin, Germany

  • Cliniques Universitaires Saint-Luc, Brussels, BelgiumThe Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, United KingdomMassachusetts General Hospital Cancer Center, Boston, MA

  • University of Montreal, Montreal, QC, Canada

  • University of Washington and Fred Hutchinson Cancer Center, Seattle, WA

Locations

  • United States

  • Germany

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • Alpharadin

  • Alkaline phosphatase

  • CB-7598

  • Prednisone

  • Radium-223 Dichloride

  • Denosumab

  • Opiate

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT02043678

Sponsors

  • Bayer

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved